



# Minimal Residual Disease in Solid Tumors

**Presenter : Reema Anil Patel, MD** 

February 28, 2025



I have nothing to disclose.

### **Learning Objectives**

Define ctDNA

Review current data across multiple solid tumors

Discuss the future


### The Basics of ctDNA

Cell free DNA (cfDNA): small DNA fragments in circulation, released via cell death


#### **Circulating tumor DNA**

(ctDNA): small fragments released from tumors in patients with cancer.

Can detect epi(genomic changes) that are cancer-specific



Early Detection Diagnosis Minimal residual disease Relapse



Therapy Selection Response to therapy Resistance

### ctDNA as a Key MRD Marker

#### **Early Detection**

ctDNA analysis allows for early detection of residual disease, potentially before clinical symptoms develop

#### Treatment Response

Monitoring ctDNA levels can help track treatment response and predict potential relapse.



## MRD in Solid Tumors (current data)



MRD in adjuvant setting is predictive and prognostic

Identifies patients at highest risk of recurrence/relapse and who may benefit most from adjuvant chemotherapy

Sustained MRD prognostic of disease free survival



In muscle invasive bladder cancer, detectable ctDNA is prognostic for recurrence

ctDNA dynamics correlated with pathologic downstaging

utDNA clearance predicts pCR, optimize selection of patients who would benefit from bladder preservation surgery

Integration of ctDNA & utDNA for surgery and adjuvant therapy

S 0 ance




MRD in resectable, locally advanced or metastatic can be prognostic , specifically clearance of KRAS mutations

Stric 



#### Detectable ctDNA perioperative prognostic

Role for intensification of adjuvant therapy?



MRD in adjuvant setting is predictive and prognostic

Identifies patients at highest risk of recurrence/relapse and who may benefit most from adjuvant chemotherapy

Sustained MRD prognostic of disease free survival

Detection of certain mutations can predict drug resistance

### **Challenges in MRD**

#### **Sensitivity and Specificity**

Achieving high sensitivity and specificity in MRD detection remains a technical challenge.

#### **Cost and Accessibility**

The high cost & turn around time of MRD testing can limit its availability for all patients.

#### Standardization

Lack of standardization across different platforms and laboratories presents a barrier to consistent results.



### **Futured of MRD**

#### **Liquid Biopsy Advancements**


Advances in liquid biopsy technologies promise more sensitive and reliable MRD detection.

#### **Artificial Intelligence (AI)**

Al-powered algorithms are being developed to improve the accuracy and speed of MRD analysis.

#### **Personalized Medicine**

MRD testing will play a crucial role in driving personalized medicine targeted therapies.



"Far and away the best prize that life offers is the chance to work hard at work worth doing."

**Theodore Roosevelt** 





### References

- Abbosh C, Birkbak NJ, Wilson GA, et al: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. *Nature* 545:446-451, 2017
- Chen K, Zhao H, Shi Y, et al: Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC). *Clin Cancer Res* 25:7058-7067, 2019
- Cook, Natalie. Is It Time to Implement ctDNA in Clinical Practice? ASCO Education 2022
- Maron SB, Chase LM, Lomnicki S, et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. *Clin Cancer Res.* 2019; 25: 7098 7112.
- Nakano Y, Kitago M, Matsuda S, et al. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study. *Br J Cancer.* 2018. Pietrasz D
- Oxnard GR, Chen X, Fung ET, et al: Prognostic significance of blood-based cancer detection in plasma cell-free DNA (cfDNA): Evaluating risk of overdiagnosis. *J Clin Oncol* 37, 2019 (suppl 15; abstr 1545)
- Pécuchet N, Garlan F, et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker. Clin Cancer Res. 2017; 23: 116 123.
- Pashtoon, M et al. Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO Precis Oncol 6, e2100181(2022).
- Priyadarshini S. Patak et al. State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation. *Am Soc Clin Oncol Educ Book* 44, e438466(2024).
- Sfakianos JP, Basu A, Laliotis G, et al: Association of tumor-informed circulating tumor DNA detectability before and after radical cystectomy with disease-free survival in patients with bladder cancer. *Eur Urol Oncol* S2588-9311(24)00174-3, 2024
- Stewart TF, Chalfin H, Simon N, et al: Perioperative use of ctDNA to guide treatment for urothelial carcinoma: The future is now. *Bladder Cancer* 10:183-198, 2024
- Tie, Jeanne. The ABCs of ctDNA. ASCO Education 2022







### THANK YOU

For more information contact

Dr. Reema Patel reema.patel@uky.edu